



Transplant Complications Working Party

Chair: Zina Peric

GvHD subcom: Olaf Penack

Regimen-related tox subcom: Christian Koenecke

Secretary: Ivan Moiseev

Survivorship subcom: Helene Schoemans

AI subcom: Grzegorz Basak

Publications in 2022

Penack O. et al. Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. *Bone Marrow Transplant.* 2022 Feb;57(2):183-190. doi: 10.1038/s41409-021-01502-8. Epub 2021 Oct 30.

Perovic V. et al. Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network. *Bone Marrow Transplant.* 2022 Jun 11. doi: 10.1038/s41409-022-01733-3. Epub ahead of print.

Waszczuk-Gajda A. et al. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. *J Clin Med.* 2022 Jun 20;11(12):3541. doi: 10.3390/jcm11123541.

Phelan R. et al. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. *Transplant Cell Ther.* 2022 Jun;28(6):335.e1-335.e17. doi: 10.1016/j.jtct.2021.10.013. Epub 2021 Oct 29.

Phelan R. et al. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2022 Jul;57(7):1150-1163. doi: 10.1038/s41409-022-01591-z. Epub 2022 May 6.

Gjærde LK. et al. Sexual function of adult long-term survivors and their partners after allogeneic hematopoietic cell transplantation in Europe (S-FAST): a study from the Transplant Complications Working Party and Nurses Group of the EBMT. *Bone Marrow Transplant.* 2022 Nov 14. doi: 10.1038/s41409-022-01869-2. Online ahead of print.

Moiseev I. et al. Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant.* 2022 Nov 29;1-3. doi: 10.1038/s41409-022-01881-6.

Piekarska A. et al. ATG or no ATG? - survey of clinical practice in EBMT centers on behalf of the Transplant Complications Working Party of EBMT. *Bone Marrow Transplant.* 2022 Dec 5. doi: 10.1038/s41409-022-01889-y. Online ahead of print.

Submitted manuscripts

- Ruutu T. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients.
- Gjærde LK. Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation
- Penack O. EASIX associates with mortality after allogeneic stem cell transplantation.
- Penack O. Severe cytopenia after CD19 CAR T-cell therapy.
- Penack O. Organ complications after CD19 CAR T-cell therapy for Large B Cell Lymphoma.

Presentations at EBMT 2023

- Pulanic. D. Chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation over 30 years.
- Gjærde LK. Pre-transplantation diabetes mellitus and obesity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
- Salas MQ. Efficacy of PTCy-based GvHD-prophylaxis in adults older than 55 with myeloid malignancies undergoing allo-HCT according to donor type.
- Penack O. ECP versus Ruxolitinib in steroid-refractory acute GvHD.
- Penack O. ECP versus Ruxolitinib in steroid-refractory chronic GvHD.

Studies planned to be completed in 2023

- Durakovic N. Graft rejection in haploidentical HSCT: survey of subsequent therapeutic options.
- Peric Z. Survey on the management of steroid-refractory graft-versus-host disease (SR-GvHD).
- Schoemans H. EBMT patient engagement taskforce (PRO).
- Penack O. NRM after second allo-SCT.
- Gorka M. The impact of blood group disparities on the outcomes of allogeneic stem cell transplantation in modern era.
- Basak G. Complications of CTX-based haploidentical stem cell transplantation – prospective observational study.
- Basak G. Association of pre-existing co-morbidities with CAR-T therapy outcome.
- Schetelig J. & de Wreede L. Treatment Related and population mortality for Older Patients (TROP).
- Bilinski J. Fecal microbiota transplantation in the treatment of acute gastrointestinal graft-versus-host disease.
- Ortí G. Graft-versus-Host Disease after donor-derived CAR-T infusion post-allogeneic HSCT.
- Mussetti A. Machine learning approach to estimate toxicity-related mortality following allogeneic HSCT.
- Turki A. Machine learning and GvHD.

Ongoing data collection and analysis

- Montoro Gomez J. & Bos S. Outcomes and risk factors for survival of lung transplantation after allogeneic HSCT.
- Moiseev I. Steroid-free first line treatment of moderate and severe chronic GvHD retrospective study.
- Gagelmann N. Daratumumab for pure red cell aplasia (PRCA) after allogeneic HSCT.
- Brijs J. Safety and efficacy of immune checkpoint inhibitors for solid organ malignancies after allogeneic HSCT.
- Penack O. Survey on the current management to prevent and treat CD19+ and BCMA+ CAR T-cell therapy-related complications.
- Mekinian A. Secondary autoimmune and inflammatory diseases (sec.AIID) post-allogeneic HSCT.
- Damm F. & Schetelig J. Effects of donor clonal hematopoiesis in unrelated hematopoietic stem cell transplantation.

Upcoming studies

- Moiseev I. Risk stratification and response criteria to interventions in transplant-associated microangiopathy (TMA).
- Schultze-Florey C. CAR-T-cell therapy-associated neurotoxicity.
- Rudakova T. Efficacy and outcomes of hematopoietic stem cell boost in adult patients with poor graft function (boost).